The company Pure Biologics, using the laboratories of the Wroclaw Technology Park, received funding from the National Center for Research and Development for the development of an innovative drug for anti-cancer immunotherapy. The total value of the project is over PLN 35 million.

The aim of the project is to develop a recombinant antibody – Multibody, which can be an immunotherapeutic drug for patients suffering from colorectal cancer – the third most common cancer diagnosed in women and the second most common in men.

The project, which is scheduled to start in the first half of 2018, will be based on a technological platform- PureSelect to search for antibody fragments with therapeutic and diagnostic potential. The solution proposed by Pure Biologics will allow the development of an innovative drug with a unique therapeutic potential. The company is ready to start the second phase of clinical tests.